SAKK 24/09: Safety and tolerability of bevacizumab plus paclitaxel versus bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer—A multicenter, randomized phase III trial.
Christoph Rochlitz
Honoraria - Roche
Roger von Moos
No relevant relationships to disclose
Martin Bigler
No relevant relationships to disclose
Khalil Zaman
No relevant relationships to disclose
Sandro Anchisi
Consultant or Advisory Role - Roche
Marc Küng
No relevant relationships to disclose
Kyung Jae Na
No relevant relationships to disclose
Daniela Baertschi
No relevant relationships to disclose
Markus M. Borner
No relevant relationships to disclose
Tamara Rordorf
No relevant relationships to disclose
Daniel Rauch
No relevant relationships to disclose
Andreas Mueller
No relevant relationships to disclose
Thomas Ruhstaller
No relevant relationships to disclose
Marcus Vetter
Honoraria - Roche
Juerg Bernhard
No relevant relationships to disclose
Andreas Trojan
No relevant relationships to disclose
Ursula Hasler-Strub
No relevant relationships to disclose
Richard Cathomas
No relevant relationships to disclose
Ralph C. Winterhalder
No relevant relationships to disclose